Skip to Content

Standard BioTools to Participate in Upcoming Investor Conferences

Jun 14, 2023

SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences:

  • Capital One Securities 2nd Annual Spatial Biology and Proteomics Virtual Research Summit: On Tuesday, June 20, at 10:30 am ET, David King PhD, Senior Vice President, Global Research and Development, will participate in the “Pushing the Envelope of Technology with Increased Sensitivity and Higher Plex on the Horizon” Panel. Dr. King will also participate in a company presentation at 2:35 pm ET.
  • TD Cowen 2nd Annual Tools/Dx Revolution: On Monday, June 26, at 4:20 pm PT, Michael Egholm, President and Chief Executive Officer, will participate in the “Spatial – The Next Frontier: Clinical” Panel.

Due to the format of these events, webcasts will not be available. Presentation materials will be available on the Investor Relations page of the company’s website at Events & Presentations

About Standard BioTools Inc. 

Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at or connect with us on Twitter®, Facebook®, LinkedIn®, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contacts: 

Scott R. Greenstone, CFA 

Peter DeNardo 
415 389 6400 

Primary Logo

Source: Standard BioTools Inc.